Targeted protein degradation (TPD) has moved from promising concept to near-commercial reality in under a decade. By hijacking the cell’s
Continue Reading Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy – March 2026 Update
Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural
Continue Reading Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy
Although the Corporate Transparency Act (the “CTA”) is no longer halted by nationwide preliminary injunctions, U.S. companies and their beneficial
Continue Reading CTA Update: Domestic Reporting Companies Exempt from Reporting to FinCEN
For the past few months, the beneficial ownership reporting obligations under the Corporate Transparency Act (the “CTA”) have fluctuated between
Continue Reading Corporate Transparency Act Requirements Are Back: March 21, 2025 Deadline Looms
Only days after lifting the nationwide preliminary injunction, the Fifth Circuit Court of Appeals vacated their decision to stay the
Continue Reading Latest Update: Corporate Transparency Act Halted Again
As an update to our posts on the ongoing attempts to block the Corporate Transparency Act, on December 23, 2024
Continue Reading Update: Corporate Transparency Act Reinstated by Appeals Court: January 1 Deadline Looms
As an update to our post on the Corporate Transparency Act, on December 3, 2024, a federal district court issued
Continue Reading Update: The Corporate Transparency Act Put On Hold
The Corporate Transparency Act (CTA) went into effect on January 1, 2024, and will impact millions of U.S. businesses by
Continue Reading The Corporate Transparency Act: What you Need to Know to Comply with the New Requirements